Correlation Between Oncopeptides and Integrum

Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Integrum at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Integrum into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncopeptides AB and Integrum AB Series, you can compare the effects of market volatilities on Oncopeptides and Integrum and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Integrum. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Integrum.

Diversification Opportunities for Oncopeptides and Integrum

0.84

Correlation Coefficient

Oncopeptides  Integrum

Very poor diversification

The 3 months correlation between Oncopeptides and Integrum is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Integrum AB Series in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Integrum AB Series and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Integrum. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Integrum AB Series has no effect on the direction of Oncopeptides i.e., Oncopeptides and Integrum go up and down completely randomly.

Pair Corralation between Oncopeptides and Integrum

Assuming the 90 days trading horizon Oncopeptides AB is expected to generate 1.41 times more return on investment than Integrum. However, Oncopeptides is 1.41 times more volatile than Integrum AB Series. It trades about -0.12 of its potential returns per unit of risk. Integrum AB Series is currently generating about -0.22 per unit of risk. If you would invest  213.00  in Oncopeptides AB on October 9, 2024 and sell it today you would lose (56.00) from holding Oncopeptides AB or give up 26.29% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Oncopeptides AB  vs.  Integrum AB Series

Oncopeptides AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Integrum AB Series

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Integrum AB Series has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Oncopeptides and Integrum

The main advantage of trading using opposite Oncopeptides and Integrum positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Integrum can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrum will offset losses from the drop in Integrum's long position.

The idea behind Oncopeptides AB and Integrum AB Series pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.